NCT07180342

Brief Summary

Empirically investigating how natural tourism activities alleviate symptoms in patients with Major Depressive Disorder through multidimensional pathways of physiological, psychological, and social functioning.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
86

participants targeted

Target at P50-P75 for not_applicable major-depressive-disorder

Timeline
17mo left

Started Oct 2025

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress30%
Oct 2025Sep 2027

First Submitted

Initial submission to the registry

September 6, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

September 18, 2025

Completed
21 days until next milestone

Study Start

First participant enrolled

October 9, 2025

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 18, 2027

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 18, 2027

Last Updated

December 16, 2025

Status Verified

December 1, 2025

Enrollment Period

1.4 years

First QC Date

September 6, 2025

Last Update Submit

December 14, 2025

Conditions

Keywords

Major Depressive DisorderTourismMMD

Outcome Measures

Primary Outcomes (1)

  • Change in Depressive Symptoms

    MADRS (Clinician-focused), Change from baseline in MADRS total score (range 0-60; higher = worse)

    Baseline, intervention day 1

Secondary Outcomes (7)

  • Response from Depression

    Baseline, 2-week follow-up

  • Remission from Depression

    Baseline, 2-week follow-up

  • Change in Depressive Symptoms

    Baseline, intervention day 1, 1-week follow-up, and 2-week follow-up

  • Change in Depressive Symptoms

    Baseline, intervention day 1, 1-week follow-up, and 2-week follow-up

  • Change in Depressive Symptoms

    Baseline, intervention day 1, 1-week follow-up, and 2-week follow-up

  • +2 more secondary outcomes

Other Outcomes (11)

  • Change in quality of life

    Baseline, 2-week follow-up

  • Change in quality of life

    Baseline, 2-week follow-up

  • Change in quality of life

    Baseline, 2-week follow-up

  • +8 more other outcomes

Study Arms (2)

Intervention Group

EXPERIMENTAL

Following the acquisition of participant consent and the signing of (electronic) informed consent forms, subjects were randomized into either an intervention group or a control group using a computer-generated randomization list. The intervention group received a tourism-based intervention, while the control group continued to receive usual care without any structured modifications to their daily living patterns or treatment plans. Both groups maintained a foundational treatment regimen of antidepressant medication.

Behavioral: Tourism-based intervention

Control Group

NO INTERVENTION

Following the acquisition of participant consent and the signing of (electronic) informed consent forms, subjects were randomized into either an intervention group or a control group using a computer-generated randomization list. The intervention group received a tourism-based intervention, while the control group continued to receive usual care without any structured modifications to their daily living patterns or treatment plans. Both groups maintained a foundational treatment regimen of antidepressant medication.

Interventions

Following the acquisition of participant consent and the signing of (electronic) informed consent forms, subjects were randomized into either an intervention group or a control group using a computer-generated randomization list. The intervention group received a tourism-based intervention, while the control group continued to receive usual care without any structured modifications to their daily living patterns or treatment plans. Both groups maintained a foundational treatment regimen of antidepressant medication.

Intervention Group

Eligibility Criteria

Age18 Years - 59 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Voluntarily participate in the study and sign the informed consent form;
  • Age between 18 (inclusive) and 60 (exclusive) at the screening period;
  • Meet the DSM-5 diagnostic criteria for a Major Depressive Episode (MDE) at enrollment, based on medical records, clinical assessment, and the Mini-International Neuropsychiatric Interview (MINI version 7.0.2);
  • Hamilton Depression Rating Scale 17-item (HAMD-17) score ≥ 17 at both screening and baseline;
  • Physically stable based on medical history and vital signs (including blood pressure);
  • Deemed by the investigator to be capable of independently completing all assessment tools required by the study protocol and willing to comply with the trial procedures throughout the study period.

You may not qualify if:

  • Current or past diagnosis of: schizophrenia, psychotic disorders (unless substance-induced or due to another medical condition), bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, borderline personality disorder, or other severe psychiatric comorbidities confirmed by medical history and structured clinical assessment using the Mini-International Neuropsychiatric Interview (MINI version 7.0.2);
  • Current or history of alcohol or substance abuse within the past year;
  • A score of ≥3 on item 3 (suicide) of the HAMD-17, suicide attempt within the past year, or clinically assessed significant suicide risk;
  • Depression secondary to other severe medical conditions (e.g., hypothyroidism, Parkinson's disease, etc.);
  • Cardiovascular diseases: stroke or myocardial infarction within the past year, hypertension (blood pressure \>140/90 mmHg), or clinically significant arrhythmia;
  • Other significant comorbid diseases that may interfere with the interpretation of study results or pose risks to participant health (e.g., cardiovascular, respiratory, gastrointestinal, hepatic, renal, or other systemic diseases), as determined by the investigator;
  • Current participation in an interventional study for Major Depressive Disorder, or participation in such a study within 30 days prior to screening;
  • Having visited Wulongtan Park, Baotu Spring Park and Daming Lake Park for a prolonged period (single stay ≥1 hour) within the past three years.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Shandong Provincial Hospital Affiliated to Shandong First Medical University

Jinan, Shandong, China

NOT YET RECRUITING

Shandong Provincial Hospital Affiliated to Shandong First Medical University

Jinan, Shandong, China

RECRUITING

MeSH Terms

Conditions

Depressive Disorder, Major

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental Disorders

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 6, 2025

First Posted

September 18, 2025

Study Start

October 9, 2025

Primary Completion (Estimated)

March 18, 2027

Study Completion (Estimated)

September 18, 2027

Last Updated

December 16, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations